[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pasc-post-acute-sequelae-of-covid-19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pasc-post-acute-sequelae-of-covid-19":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,74,97,128,151,176,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100645261","phase-1-taurine-supplementation-in-adolescents-with-post-covid-condition-100645261",false,"NCT07682402","Taurine Supplementation in Adolescents With Post-COVID Condition","An Open-Label Study of Taurine Supplementation in Adolescents With Post-COVID Condition: Quantifying Taurine Plasma Levels and Evaluating Clinical and Biological Outcomes","TaurineLCPeds","Inclusion Criteria:\n\n1. Subjects must be between 10 and 17 years of age at the time of study enrollment\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to trial; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to trial enrollment.\n3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.\n5. Lingering symptoms from COVID-19 present at the time of trial enrollment.\n6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Medication(s) only available through a prescription for the purposes of treating fatigue or cognitive function have been discontinued for four weeks prior to randomization.\n8. Participants must be able to assent to their participation in the study and be both willing and able to comply with study requirements.\n9. Parents\u002Fcaregivers\u002Fguardians must be able to provide informed consent for participation.\n10. Participants must agree to avoid taking supplemental taurine (e.g. from over-the-counter preparations, energy drinks, etc.)\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.\n2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.\n3. Contraindications to the study intervention.\n4. Currently already on the study intervention (Participants would be eligible if they stopped taking Taurine for a minimum of 4 weeks prior to enrollment).\n5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted).\n6. Currently pregnant or breastfeeding.\n7. The participant is currently enrolled in another research trial to treat neurocognitive symptoms in LC.","ALL","10 Years","17 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19 (PASC), has emerged as a complex multisystemic condition and challenging public health issue.\n\nContrary to initial perceptions, pediatric Long COVID is a significant health concern, with studies suggesting its prevalence ranges from 10% to 25% following infection. Research in the pediatric population has largely been limited to observational studies based on self-reported symptoms or large electronic healthcare datasets. The long-term outcomes and predictors of LC in children remain poorly described, highlighting an urgent need for further mechanistic research to characterize this complex condition. While acute COVID-19 symptoms are often milder in children relative to adults, some go on to develop a range of chronic physical, immunological, psychological, and neurological symptoms persisting for weeks to years after initial infection. The most commonly reported symptoms are similar to those seen in adults and include debilitating fatigue, respiratory distress, headaches, gastrointestinal symptoms, and neurocognitive impairment. Other frequently reported symptoms include muscle pain, sleep disturbances, olfactory and gustatory disturbances, exercise intolerance, and heart palpitations\u002Fcardiovascular symptoms. These symptoms can be new, or they may persist or fluctuate from the initial illness. Additionally, many children with LC experience psychological symptoms such as anxiety, depression, and mood disturbances, which are thought to be exacerbated by experiencing prolonged illness and subsequent lifestyle disruptions.\n\nCurrently, effective treatments for LC remain elusive, leaving patients to contend with persistent symptoms that significantly impair their quality of life. For children and adolescents, these issues can profoundly impact their daily activities, academic performance, and social interactions\u002Ffriendships. Symptoms like debilitating fatigue, cognitive impairment, and mood disturbances are especially disruptive by interfering with memory, energy levels, and overall development, often leading to school absenteeism, social withdrawal, and psychological distress. Therefore, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.",[29,30,31],"Long COVID","Post COVID-19 Condition","PASC Post Acute Sequelae of COVID 19","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":22},"2026-09-30",{"date":40,"type":22},"2028-12-31",{"name":42,"class":43},"University of Alberta","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100560463","cross-sectional-evaluation-of-persistence-of-sars-cov-2-remnants-after-recovery-from-acute-infection-100560463","NCT06577467","Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection","* INCLUSION CRITERIA:\n\nRecovered Volunteers (RV): Six healthy persons who have recovered from an acute SARS-CoV-2 infection.\n\nInclusion criteria:\n\n* Participants 18 and older\n* Ability to provide informed consent\n* Completed participation in Phase B of Protocol 000089\n* Met 000089 Inclusion criteria for Mild to Moderate COVID-19 without PASC symptoms:\n\n  * Licensed Independent Practitioner documentation of a stable state of general well-health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.\n  * A self-reported illness narrative of recovery to prior health after a SARS\u002FCoV2 infection.\n  * Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive anti-SARS nucleocapsid antibody test.\n  * Meets WHO Clinical Progression Scale of 2 - 6:\n\n    2: Ambulatory; symptomatic, independent\n\n    3: Ambulatory; symptomatic, assistance needed\n\n    4: Hospitalized; no oxygen therapy\n\n    5: Hospitalized; oxygen by mask or nasal prongs\n\n    6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen\n  * Functional Criteria: No substantial symptom severity as determined using SF-36v2: score of \\>=85 physical function subscale, and \\>=85 on role physical subscale, and \\>=85 on social function subscale.\n* Determined to be a Healthy Comparator by the 000089 Case Adjudication Committee\n* Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and\u002For testing. Testing may be repeated with each admission. Participants may be rescreened 6 weeks after acute infection has resolved.\n\nNeurologic Post-Acute Sequelae of COVID-19 Participants (Neuro-PASC):\n\nSix persons with ongoing neurological complaints following an acute SARS-CoV-2 infection.\n\nInclusion criteria:\n\n* Participants 18 and older\n* Ability to provide informed consent\n* Completed participation in Phase B of Protocol 000089\n* Met 000089 Inclusion criteria for Mild to Moderate COVID-19 with PASC symptoms:\n\n  * Licensed Independent Practitioner documentation of a stable state of general well-health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.\n  * A self-reported illness narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, unrefreshing sleep, neuropathic pain, mood change, and post-exertional malaise.\n  * Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive anti-SARS nucleocapsid antibody test .\n  * Meets WHO Clinical Progression Scale of 2 - 6:\n\n    2: Ambulatory; symptomatic, independent\n\n    3: Ambulatory; symptomatic, assistance needed\n\n    4: Hospitalized; no oxygen therapy\n\n    5: Hospitalized; oxygen by mask or nasal prongs\n\n    6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen\n  * Functional Criteria: Substantial symptom severity as determined using SF-36v2: score of \\\u003C= 70 physical function subscale, or \\\u003C=50 on role physical subscale, or \\\u003C=75 on social function subscale.\n* Determined to have Post-Acute Sequelae of COVID-19 by the 000089 Case Adjudication Committee\n* Primary PASC complaint is neurologic including:\n\n  * Neuropathic sensations\n  * Cognitive complaints\n  * Postural (Orthostatic) complaints\n  * Motor complaints\n* Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and\u002For testing. Testing may be repeated with each admission. Participants may be rescreened 6 weeks after acute infection has resolved.\n\nEXCLUSION CRITERIA:\n\n* Current suicidal ideation\n* Women who are pregnant, breastfeeding, or are within one-year post-partum.\n* Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.\n* Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis). Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed.\n* Current or previous long-term immune suppressive therapy. Systemic steroid use, even short-term, must not have been used within the month prior to enrollment.\n* Long term use of anticoagulant or antiplatelet medications.\n* Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study.\n* Not willing to allow for research data and samples to be shared broadly with other researchers.\n* Employees of NIH.\n* Symptom severity that makes it impossible for the volunteer to travel to NIH for an extended inpatient evaluation\n* Use of medications with a high-risk for withdrawal-related complications (i.e. long-acting opiates or benzodiazepines).\n* Unwillingness to co-enroll in protocol 17-I-0122: NIAID Centralized Sequencing Protocol.",true,"18 Years","110 Years",{"count":54,"type":22},12,"OBSERVATIONAL","Background:\n\nSARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends. This is called long COVID. Sometimes, long COVID can affect the nerves and cause problems with sleep, thinking, the senses, and movement. Researchers want to find out whether people with long COVID have retained inactive remnants of SARS-CoV-2 in their bodies.\n\nObjective:\n\nTo collect tissue samples to see if people with long COVID have remnants of SARS-CoV-2 in their bodies.\n\nEligibility:\n\nPeople 18 years or older who have recovered from COVID-19, both with and without neurologic symptoms.\n\nDesign:\n\nParticipants will have 2 to 6 inpatient or outpatient visits over 4 months. Each visit will last 4 to 5 days.\n\nParticipants will be screened to make sure it is safe to collect tissue samples from their body. They will have a physical and dental exam. They will have imaging scans and a test of their heart function. They will complete questionnaires about their health. They will give blood, urine, saliva, and stool samples. Their sense of taste and smell will be tested.\n\nTissue samples will be taken from the digestive tract, lungs, colon, skin, muscle, lymph nodes, nasal passages, and mouth. Participants may be numbed or sedated for some of the procedures.\n\nSwabs will be used to collect cells from inside the mouth and nose.\n\nParticipants will undergo lumbar puncture. A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.\n\nParticipants will have follow-up phone calls after each clinic visit.",[58],"PASC Post Acute Sequelae of COVID-19",[60,61],"PASC","COVID-19","RECRUITING","2026-06-03",{"date":65,"type":36},"2026-06-04",{"date":67,"type":36},"2025-03-27",{"date":69,"type":22},"2027-09-01",{"name":71,"class":72},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100598851","early-phase-1-multiparametric-18ff-arag-imaging-in-post-acute-sequelae-of-covid-19-pasc-100598851","NCT07076862","Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)","Multiparametric Total-Body [18F]F-AraG PET\u002FCT Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to understand the purposes and risks of the trial and willingness to sign an IRB-approved informed consent form.\n3. Willingness and ability to comply with all protocol required procedures.\n4. For participants of reproductive potential, defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy, willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) during the study and up to 1 day after the last administration of the radiotracer.\n5. Previous diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples or from an FDA-approved rapid antigen test at home. Documentation of the positive test will be requested but not required; if not available the participant will be asked to attest to the presence of a positive test.\n6. Onset of COVID-19 symptoms (or if no symptoms, time of initial nucleic acid or antigen-based diagnostic test) at least 3 months prior to the baseline study visit.\n7. Ability to travel to our research sites in San Francisco and Sacramento.\n8. Laboratory evaluations obtained within 60 days prior to entry:\n\n   1. Hemoglobin ≥ 8g\u002FdL\n   2. Platelet count ≥ 75,000 cells\u002Fmm3\n   3. Absolute neutrophil count (ANC) \\> 1000 cells\u002Fmm3\n   4. Aspartate aminotransferase (AST) \\\u003C 3 × ULN units\u002FL\n   5. Alanine aminotransferase (ALT) \\\u003C 3 × ULN units\u002FL\n   6. Calculated creatinine clearance (CrCl) ≥ 60mL\u002Fmin as estimated by the Cockcroft-Gault equation:\n\n   For men, (140 - age in years) × (body weight in kg) ÷ (serum creatinine in mg\u002FdL × 72) = CrCl (mL\u002Fmin)\\*\n\n   \\*For women, multiply the result by 0.85 = CrCl (mL\u002Fmin)\n9. For PASC participants only: Reporting at least 2 unexplained symptoms, with at least 1 symptom in the fatigue domain and at least 1 symptom in either cardiopulmonary or neurocognitive domains, that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset after initial COVID-19 recovery or persist from the initial acute phase and may fluctuate or relapse over time. (According to World Health Organization definition of PASC http:\u002F\u002Fwww.WHO.int )\n10. For control participants only: Individuals who have made full clinical recovery within 4-12 weeks of acute COVID-19 infection with no newly developed symptoms or changes in health after recovery.\n\nExclusion Criteria:\n\n1. Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the investigator could compromise protocol objectives.\n2. Any condition that alters the function of their immune system or any conditions caused by malfunction of their immune system and would interfere with imaging, including known underlying inflammatory or immune disorders, systemic malignancy, or other chronic viral infections (such as HIV, hepatitis B and hepatitis C).\n3. Received vaccination of any type, including a SARS-CoV-2 vaccine, within 30 days of imaging\n4. Pregnant or nursing individuals. A urine or HCG serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL will be performed at screening and on the day of PET\u002FCT imaging at no charge to all participants of reproductive potential (see definition above).\n5. Participants who have had prior allogeneic stem cell or solid organ transplant.\n6. Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry.\n7. Active systemic autoimmune diseases not related to COVID-19.\n8. Self-reported history of dysphoria or anxiety in closed spaces (i.e., uncontrolled claustrophobia).\n9. Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n10. Body weight is more than 240 kg (529 pounds)\n11. Prisoners\n12. Life expectancy \\\u003C 24 months\n13. Recent use of medication including guanosine or cysteine analogs.\n14. Any other criteria which would make the participant unsuitable for enrollment to this study, as determined by the Principal Investigator.",{"count":82,"type":22},51,[84],"EARLY_PHASE1","This study uses total-body \\[¹⁸F\\]F-AraG PET\u002FCT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET\u002FCT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.",[58],"2026-05-19",{"date":89,"type":36},"2026-05-22",{"date":91,"type":36},"2025-12-04",{"date":93,"type":22},"2029-12",{"name":95,"class":43},"University of California, Davis",2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":73},"100614331","brain-stimulation-in-long-covid-100614331","NCT07278206","Brain Stimulation in Long COVID","Mitigating Cognitive Problems and Fatigue With Brain Stimulation in Long COVID","MALIBU","Inclusion Criteria:\n\n* Meet the World Health Organization (WHO) definition of long COVID.\n* Aged 18 years or older.\n* Severe fatigue, defined as a score ≥35 on the Checklist Individual Strength (CIS) fatigue subscale.\n* Significant cognitive complaints, defined as a score ≥18 on the CIS concentration subscale.\n* Commitment to actively undergo rTMS\n* Ability to attend the study site regularly for treatment sessions.\n* Capacity to provide written informed consent.\n\nExclusion Criteria:\n\n* Prior rTMS treatment or current intensive\u002Fexperimental treatment for long COVID.\n* History of epilepsy or first-degree family history of epilepsy.\n* Recent initiation or dosage change of psychotropic medication (less than six weeks for psychotropic medication including antidepressants and antipsychotic drugs, less than two weeks for benzodiazepines). Medication doses must remain stable during the study.\n* Other active concurrent pharmacological treatments for post-covid symptoms\n* Contraindications to MRI scanning (e.g., non-removable metallic implants, severe claustrophobia).\n* Presence of a cochlear implant.\n* Neurological disorders such as multiple sclerosis or other neurodegenerative conditions.\n* Pregnancy.\n* Known brain lesions or ischaemic scars influencing seizure threshold.\n* Severe uncontrolled migraines.\n* Severe cardiovascular disease\n* Raised intracranial pressure.\n* High alcohol consumption (males\u002Ffemales: 21\u002F14 units per week) or use of epileptogenic drugs.\n* Severe sleep deprivation at the time of treatment.",{"count":106,"type":22},66,[108],"NA","Cognitive problems and severe fatigue are two frequently occurring symptoms in long COVID, also known as Post-Covid Condition or Post-Acute Sequelae of COVID-19 (PASC), and their causes are currently unknown. Previous studies have shown reduced blood flow and increased inflammation in the brains of people with PASC. These brain processes are related to fatigue and cognitive problems. In other conditions, these disrupted brain processes have been treated safely and successfully with non-invasive brain stimulation. This may offer an effective treatment for people with PASC.\n\nThe main goal of this clinical trial is to see whether non-invasive brain stimulation called repetitive transcranial magnetic stimulation (rTMS) can reduce fatigue in adults with PASC who also have trouble concentrating. rTMS uses short magnetic pulses on the scalp to gently stimulate a small brain area.\n\nIn this study, 66 adults with PASC will be included, recruited through the Post-COVID Network Netherlands. Participants will be randomly assigned to receive either active rTMS or sham (placebo) rTMS. Sham rTMS feels and looks similar to the active treatment, but it does not generate effective magnetic pulses. The brain area that will be targeted is personalized using a brain scan (MRI) during a planning task. All participants will receive 24 rTMS sessions over six weeks (four per week).\n\nFatigue will be measured within two weeks before and two weeks after treatment to determine whether active rTMS works better than sham. We will also look at cognition, brain connectivity and blood flow, signs of (neuro)inflammation, daily activity using an activity watch, and questionnaires about quality of life, mood, and sleep. Follow-up on cognition and questionnaires will take place 3 and 6 months after the end of the treatment.",[29,31,111],"Post COVID-19 Condition (PCC)",[113,60,114,115,116,117,118],"TMS","long COVID","PCC","neuroimaging","non-invasive brain stimulation","transcranial magnetic stimulation","2025-12-18",{"date":121,"type":36},"2025-12-19",{"date":123,"type":36},"2025-11-17",{"date":125,"type":22},"2029-05-12",{"name":127,"class":43},"Amsterdam UMC, location VUmc",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":73},"100614345","neural-mechanisms-of-fatigue-in-post-acute-sequela-of-sars-cov-2-100614345","NCT07278388","Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2","Motivated Decision-Making and Performance","Inclusion Criteria:\n\n* Age 18 to 75 years old.\n* Have received a clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)\u002Flong COVID syndrome using the criteria specified by Thaweethai, et al., 2023 (JAMA). This symptom checklist provides a score based on the number and severity of symptoms. An individual with a score \\>12 is classified as having PASC.\n* Currently experiencing Fatigue\u002FBrain Fog as assessed with the Post-COVID symptom checklist and the PedsQL questionnaire.\n\nExclusion Criteria:\n\n* Neurological disorders including, but not limited to, stroke, head injury, epilepsy, seizures, brain tumors, brain surgery, Parkinson's Disease, or any other neuromuscular disease (self-report).\n* Diagnosed history of severe psychiatric diseases such as depression and schizophrenia (self-report).\n* Congestive heart failure.\n* Peripheral artery disease with claudication.\n* Cancer.\n* Pulmonary or renal failure.\n* Unstable angina.\n* Uncontrolled hypertension (more than 190\u002F110 mmHg).\n* Severe aphasia.\n* Orthopedic or pain conditions.\n* Have had exposure to metal or metal implants, due to the hazardous effects of the magnetic field.\n* If on immunomodulatory therapy, they must have been on that therapy for at least 6 months before the start of the study.\n\nHealthy age- and sex-matched controls for PASC - Exclusion criteria: Participants with a history of any of the following will be excluded from the study:\n\n* Hospitalization due to SARS-CoV-2 infection.\n* Neurological disorders including, but not limited to, stroke, head injury, epilepsy, seizures, brain tumors, brain surgery, Parkinson's Disease, or any other neuromuscular disease (self-report).\n* Diagnosed history of severe psychiatric diseases such as depression and schizophrenia (self-report).\n* Congestive heart failure.\n* Peripheral artery disease with claudication.","75 Years",{"count":137,"type":22},200,[108],"This proposal aims to understand the neurobiological mechanisms of fatigue in individuals with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). This knowledge will eventually provide candidate mechanisms to target with pharmacological intervention and inform rehabilitative care for those individuals suffering from symptoms of fatigue in PASC.",[31,141],"Fatigue","2025-12-01",{"date":144,"type":36},"2025-12-12",{"date":146,"type":36},"2025-07-16",{"date":148,"type":22},"2029-12-31",{"name":150,"class":43},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":73},"100588377","phase-2-magnetic-resonance-analysis-of-neural-inflammatory-factors-and-external-stimulation-100588377","NCT06940609","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)","MANIFEST","Inclusion Criteria:\n\n1. aged 18-80\n2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List\n3. have \"brain fog\" or cognitive difficulties as one of the ongoing symptoms\n4. are fluent in English\n5. if taking psychotropic medications, have been on stable doses for the past month.\n\nExclusion Criteria:\n\n1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation\n3. history of ongoing substance\u002Falcohol dependence, to reduce confounding effects on diagnosis and brain imaging\n4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS\n5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study\n6. any condition that would prevent the subject from completing the protocol\n7. appointment of a legal representative, to avoid coercion of a vulnerable population\n8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings\n9. any contraindication to MRI\n10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.","80 Years",{"count":161,"type":22},60,[26],"The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are:\n\n* Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire.\n* Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation.\n\nResearchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms.\n\nParticipants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.",[29,165,166,60,31],"Long COVID Syndrome","Long COVID-19 Syndrome","2025-07-11",{"date":169,"type":36},"2025-07-15",{"date":171,"type":36},"2025-07-07",{"date":173,"type":22},"2029-06-30",{"name":175,"class":43},"University of New Mexico",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":50,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100586138","from-inflammation-to-remodelling-towards-personalized-diagnosis-in-post-acute-sequelae-of-covid-19-100586138","NCT06911476","From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","From Inflammation Biomarkers to Remoddeling (FAPI PET\u002FCT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","LIBERATE","Inclusion Criteria:\n\n\\- Self-reported complaints of dyspnea or fatigue \\> 3 months after SARS-CoV-2 infection confirmed with PCR, serology test or COVID-19 Reporting and Data System (CO-RADS) score 4\u002F5.\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the PET\u002FCT scans.\n* Individuals who are pregnant or currently breastfeeding are not eligible to participate","20 Years",{"count":161,"type":22},"Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that \\[68Ga\\]FAPI Positron Emission Tomography-Computed Tomography (PET\u002FCT) imaging shows potential for diagnosis and molecular understanding of this syndrome. We have previously shown that fibroblast activation protein (FAP) can be imaged in the lung, muscle and nasopharynx of long COVID patients (with dyspnea and fatigue). However, these preliminary data are derived from a selective group of patients with long COVID after critical COVID-19. We aim to explore the generalizability of these findings in patients with long COVID with dyspnea and fatigue, irrespective of the severity of their acute SARS-CoV-2 infection.\n\nPrimary objective: To assess if pulmonary fibroblast activity, measured by \\[68Ga\\]FAPI-46 PET\u002FCT, is higher in patients with current long COVID dyspnea and fatigue compared to patients with resolved complaints.\n\nStudy design: This is a ZonMw funded single centre prospective observational cohort study of long COVID-19 patients with dyspnea and fatigue.\n\nStudy population: We will recruit 60 adult long COVID patients (aged \\>20 years) of which 30 have complaints of dyspnea and fatigue and compare them to 30 patients with resolved complaints and healthy controls.\n\nMain study parameters\u002Fendpoints: The primary endpoint is FAP expression in the lung measured by \\[68Ga\\]FAPI-46 PET\u002FCT. Secondary endpoints are the expression of FAP in other tissues (muscle) and the relation between FAP and inflammation and remodelling biomarkers in various biological samples (e.g. serum\u002Fnasal epithelium).\n\nStudy procedures: In a single visit day the following data and samples will be collected: questionnaires, a lung function test, 6-minute walking test, blood samples, nose swabs, \\[68Ga\\]FAPI PET\u002FCT scan and HRCT scan. When increased \\[68Ga\\]FAPI uptake is measured in the muscles a muscle biopsy will be performed as well.",[31,29,188,60,189,190,191,192,193],"Long Covid-19","FAPI","FAP","Fibroblast Activation Protein Inhibitor","Fibroblast","Restrictive Lung Disease","2025-04-03",{"date":196,"type":36},"2025-04-04",{"date":198,"type":22},"2025-05",{"date":200,"type":22},"2025-12",{"name":202,"class":43},"University Medical Center Groningen",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":96},"100583715","physiological-and-qol-benefits-of-qi-gong-in-post-acute-sequelae-of-covid-19-100583715","NCT06879925","Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19","The Effects of Qi-gong on Physiology and Quality of Life in Patients with Post-acute Sequelae of Covid-19","QG-PASC","Inclusion Criteria:\n\n* PASC\n* above 20 y\u002Fo\n\nExclusion Criteria:\n\n* Those who cannot cooperate\n* Severe schizophrenia","100 Years",{"count":213,"type":22},80,[108],"The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).\n\nStudy Objectives:\n\nTo assess whether Qi-Gong improves physiological function in individuals with PASC.\n\nTo evaluate whether Qi-Gong enhances quality of life in individuals with PASC.\n\nStudy Design:\n\nIf a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.\n\nParticipant Involvement:\n\nPractice Qi-Gong three times per week for three months. Record physiological data monthly.",[31],"2025-03-12",{"date":219,"type":36},"2025-03-17",{"date":221,"type":36},"2024-12-02",{"date":223,"type":22},"2025-04-07",{"name":225,"class":43},"POCHIWU"]